NEW YORK (GenomeWeb News) – Life Technologies today announced that it has signed a research agreement and licensing deal with Harvard University focused on stem cell assays.

The firm said that it has acquired exclusive rights from Harvard to develop a panel of characterization assays designed to rapidly evaluate human pluripotent stem cells for their use in a variety of discovery and translational research applications. The panel is expected to be offered on Life Tech's Ion Torrent semiconductor sequencing platforms, as well as its PCR-based systems.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.

Sponsored by
Thermo Fisher Scientific

In this webinar, the first in the “New Frontiers in Liquid Biopsy Research” series, Bea Bellosillo, head of pathology at the Hospital del Mar, will discuss her experience evaluating an early-access lung cancer panel that detects copy number variants and fusions.